Tinnitus Treatments from Neurodegenerative Research

Tinnitus, the perception of sound without an external source, involves more than just the ear. A new review by J. L. Liu and Peng Liu proposes that its development in the brain shares fundamental mechanisms with conditions like Alzheimer’s and Parkinson’s disease. The authors argue this overlap presents a direct opportunity: to repurpose drugs developed for neurodegenerative disorders as new tinnitus treatments.

Shared Pathology: When Tinnitus Resembles Neurodegeneration

The core argument from Liu and Liu is that the brain changes causing persistent tinnitus are not unique. Their analysis, published in Frontiers in Aging Neuroscience, identifies four overlapping processes. First, neuroinflammation—an immune response in the brain—creates a hostile environment that can damage neurons and circuits. Second, excitotoxicity occurs when neurons are overstimulated by the neurotransmitter glutamate to the point of injury or death. Third, synaptic dysfunction disrupts communication between neurons. Finally, these issues drive aberrant neural network reorganization, where the brain’s auditory and attention systems rewire in maladaptive ways, essentially “learning” the tinnitus signal. This framework moves beyond viewing tinnitus as a simple ear problem to understanding it as a whole-brain network disorder with a recognizable pathological profile.

Three Promising Avenues for Drug Repurposing

The researchers systematically examined how existing neurodegenerative strategies could intervene in these shared pathways.

1. Calming Brain Inflammation

Drugs designed to suppress chronic brain inflammation are a primary candidate. In animal models of tinnitus, inhibiting specific inflammatory signals, like tumor necrosis factor-alpha (TNF-α), has been shown to reduce tinnitus-like behavior. This approach directly targets the inflammatory environment believed to sustain the condition. The potential link between inflammation and sound sensitivity is also explored in research on pain hyperacusis, where similar inflammatory mechanisms may contribute to sound-induced pain.

2. Supporting Neuron Survival and Health

Neurotrophic factors, such as Brain-Derived Neurotrophic Factor (BDNF), act like fertilizer for neurons, promoting their survival and proper function. In neurodegeneration, boosting these factors is a key therapeutic goal. For tinnitus, enhancing BDNF signaling through its receptor, TrkB, could help protect auditory neurons and stabilize misbehaving circuits. This principle is already under investigation for other auditory injuries, as seen in work on blast trauma recovery via TrkB.

3. Blocking Glutamate Excitotoxicity

This may be the most direct translation. Drugs like memantine, used in Alzheimer’s disease, work by blocking NMDA receptors to prevent glutamate overstimulation. Given that excessive glutamate activity is a suspected trigger for tinnitus-related neural changes, such glutamate antagonists are strong candidates for repurposing. Early clinical trials have explored them, though with mixed results, highlighting the need for better patient stratification and dosing strategies.

From Animal Models to Human Trials: The Translational Gap

While the preclinical evidence is compelling, Liu and Liu note a significant gap in translation. Many compounds effective in rodent models of tinnitus have not yet moved into large-scale, conclusive human trials. The challenge lies in identifying which patients, based on their specific “tinnitus subtype” or underlying pathology, would benefit most from an anti-inflammatory versus an anti-excitotoxicity drug. This precision medicine approach is the logical next step. The review suggests that lessons from the broader field of tinnitus treatment and neurodegenerative disease insights will be essential for designing these smarter trials.

Practical Implications for Treatment Development

This research strategy offers a practical advantage: speed. Repurposing existing, safety-tested drugs can bypass much of the early development pipeline, potentially bringing new tinnitus options to patients faster. For clinicians and patients, it reframes tinnitus as a treatable neurological condition, not an untreatable life sentence. It also underscores the importance of brain health. Managing factors that exacerbate neuroinflammation—such as poor sleep, which is a common companion to tinnitus—could be a supportive strategy. Resources like an evidence-based sleep hygiene guide may offer helpful adjunctive support, given the strong bidirectional link between sleep disruption and neurological distress.

The work by Liu and Liu provides a clear, evidence-based roadmap. By targeting the common biological roots of tinnitus and neurodegeneration, researchers have a new set of tools to finally develop effective, disease-modifying therapies for the millions living with chronic tinnitus.

Source: Liu JL, Liu P. (2026). Repurposing Neurodegenerative Disease Therapeutics for Tinnitus Intervention: Mechanisms and Opportunities. Front. Aging Neurosci. doi:10.3389/fnagi.2026.1835649